Expanded FORWARD Trial Demonstrates Continued Potential for Stem Cell-Derived Islet Cell Therapy to Eliminate Need for Insulin for People with T1D
American Diabetes Association Symposium Shows Patients with Type 1 Diabetes Experienced Insulin Independence and Elimination of Severe Hypoglycemic Events with Novel Therapy
Despite use of advanced diabetes technologies, a recent survey of individuals with type 1 diabetes revealed that approximately 6% of people experience recurrent severe hypoglycemic events and have impaired awareness of hypoglycemia. Hypoglycemia, known as low blood glucose, is common in individuals with type 1 diabetes. People with type 1 diabetes may develop impaired awareness of hypoglycemia over time, meaning they may not feel symptoms despite blood glucose readings falling below a level that may provoke symptoms. If left untreated, this can lead to severe hypoglycemic events (SHEs) which can present as confusion, coma, seizures, cardiovascular events, and even death. Currently, there are limited treatment options beyond exogenous insulin for the management of the disease, creating a substantial unmet medical need for those living with type 1 diabetes.
The phase 1/2, open-label three-part study enrolled adults with type 1 diabetes, impaired hypoglycemic awareness, and at least two SHEs in the year before screening. The study evaluated the use of VX-880, an investigational, allogeneic, stem cell-derived, fully differentiated insulin-producing islet cell therapy. Participants had an average age of approximately 44 years, mean HbA1c 7.8%, total daily insulin use of approximately 40 units per day, and had experienced between two and four SHEs in the year prior to screening, and all participants had undetectable C peptide at baseline - a sign that your body is producing insulin.
Participants who received a full dose of VX-880 as a single infusion demonstrated engraftment of islet cells and endogenous insulin (C-peptide) production, eliminated severe hypoglycemic events, and significantly improved glycemic control while simultaneously reducing or eliminating insulin use. All 12 participants achieved a reduction in HbA1c to 70%.
Of 10 participants who completed the Day 180 visit: seven are no longer using exogenous insulin and two had approximately 70% reduction in their daily insulin use. Notably, 100% of patients with greater than one year of follow-up met the criteria for the primary endpoint of eliminating SHEs with HbA1c
"This positive data adds to the growing body of evidence for VX-880's potential to revolutionize the treatment of type 1 diabetes that would give patients an alternative solution other than exogenously administered insulin," said
The trial has been further expanded to enroll a total of approximately 37 participants in order to generate clinical data that will support the goal of making VX-880 available for people living with type 1 diabetes in the future.
Research presentation details:
- Symposium - Joint ADA/IPITA Symposium
Clinical Beta-Cell Replacement Therapy Today - Presented on
Friday, June 21, 2024 at3:45 PM EDT
About the ADA's Scientific Sessions
The ADA's 84th Scientific Sessions, the world's largest scientific meeting focused on diabetes research, prevention, and care, will be held in
About the American Diabetes Association
The American Diabetes Association (ADA) is the nation's leading voluntary health organization fighting to bend the curve on the diabetes epidemic and help people living with diabetes thrive. For 83 years, the ADA has driven discovery and research to treat, manage, and prevent diabetes while working relentlessly for a cure. Through advocacy, program development, and education we aim to improve the quality of life for the over 136 million Americans living with diabetes or prediabetes. Diabetes has brought us together. What we do next will make us Connected for Life®. To learn more or to get involved, visit us at diabetes.org or call 1-800-DIABETES (1-800-342-2383). Join the fight with us on Facebook (American Diabetes Association), Spanish Facebook (Asociación Americana de la Diabetes), LinkedIn (American Diabetes Association), Twitter (@AmDiabetesAssn), and Instagram (@AmDiabetesAssn).
Media contact
[email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/expanded-forward-trial-demonstrates-continued-potential-for-stem-cell-derived-islet-cell-therapy-to-eliminate-need-for-insulin-for-people-with-t1d-302178663.html
SOURCE American Diabetes Association
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2024 ASCAP TOP RHYTHM & SOUL MUSIC AWARD WINNERS INCLUDE SONGWRITER OF THE YEAR LIL BABY, SONG OF THE YEAR "SNOOZE" AND PUBLISHER OF THE YEAR WARNER CHAPPELL
- iHuman Inc. Announces First Quarter 2024 Unaudited Financial Results
- Anycubic Showcases Two Latest Intelligent 3D Printers at US Rapid+TCT 2024
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
TwitterSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!